Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 511 to 520 of 1447 total matches.
Drugs for Psychotic Disorders
The Medical Letter on Drugs and Therapeutics • Dec 19, 2016 (Issue 1510)
antipsychotics may be useful when
adherence is a problem.
161
The Medical Letter ® Vol. 58 (1510) December 19 ...
Oral antipsychotic drugs used for treatment of
schizophrenia, schizoaffective disorder, delusional
disorder, and other manifestations of psychosis or
mania are listed in Table 1. Parenteral
antipsychotic drugs used for treatment of these
disorders are listed in Table 2.
Sublingual Nitroglycerin Powder (GoNitro)
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
The Medical Letter ® Vol. 58 (1509) December 5, 2016
CONCLUSION — Sublingual nitroglycerin powder
(GoNitro ...
The FDA has approved a sublingual powder formulation
of nitroglycerin (GoNitro – Espero) for prevention
or acute relief of an attack of angina pectoris. It
is the first powder formulation of nitroglycerin to
become available in the US. Most patients with
angina use sublingual nitroglycerin tablets (Nitrostat,
and generics). Translingual spray formulations of
nitroglycerin (NitroMist, Nitrolingual Pumpspray, and
generics) are also available.
Ciprofloxacin/Fluocinolone (Otovel) for Otitis Media with Tympanostomy Tubes
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
every 8 hours
for 8 days. Clinical cure (score of 0 for symptoms of
154
The Medical Letter ® Vol. 58 ...
The FDA has approved Otovel (Arbor), a combination
of the fluoroquinolone antibiotic ciprofloxacin 0.3% and
the corticosteroid fluocinolone acetonide 0.025%, for
otic treatment of acute otitis media with tympanostomy
tubes (AOMT) in children ≥6 months old. It is the
second fluoroquinolone/corticosteroid combination
to be approved for this indication; ciprofloxacin 0.3%/dexamethasone 0.1% (Ciprodex) has been available
for many years. In December 2015, a suspension
of ciprofloxacin 6% (Otiprio) was approved for otic
treatment of bilateral otitis media with effusion in
children...
Ameluz for Actinic Keratoses
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
. All rights reserved. ©2016. www.fdbhealth.com/policies/drug-pricing-policy.
156
The Medical Letter ® Vol ...
The FDA has approved a 10% nanoemulsion gel
formulation of the porphyrin-based photosensitizer
aminolevulinic acid hydrochloride (ALA; Ameluz –
Biofrontera) for use in combination with a narrowband
red light photodynamic therapy (PDT) lamp (BF-RhodoLED)
for treatment of actinic keratoses (AKs)
of mild to moderate severity on the face and scalp.
A 20% ALA solution (Levulan Kerastick) approved for
use in combination with blue light PDT (BLU-U) has
been available in the US since 2002.
Drugs for Head Lice
The Medical Letter on Drugs and Therapeutics • Nov 21, 2016 (Issue 1508)
received
151
The Medical Letter ® Vol. 58 (1508) November 21, 2016
Table 2. Some Drugs for Head Lice ...
Head lice infestation occurs in all age groups, but especially
in elementary school children. In most cases,
transmission occurs by head-to-head contact.
Minimed 670G: A Hybrid Closed-Loop Insulin Delivery System
The Medical Letter on Drugs and Therapeutics • Nov 21, 2016 (Issue 1508)
of the study period and
148
The Medical Letter ® Vol. 58 (1508) November 21, 2016
switched to auto mode ...
The FDA has approved the Minimed 670G (Medtronic),
a hybrid closed-loop insulin delivery system for use in
patients ≥14 years old with type 1 diabetes. The system
uses an algorithm to automatically adjust basal insulin
doses based on readings from a continuous glucose
monitor (CGM). It fully automates basal insulin
delivery in "auto" mode, but is considered a "hybrid"
system (not a true "artificial pancreas") because it
requires some action by the patient. The 670G system
is expected to become available in Spring 2017.
Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
The Medical Letter on Drugs and Therapeutics • Nov 21, 2016 (Issue 1508)
The Medical Letter ® Vol. 58 (1508) November 21, 2016
DRUG INTERACTIONS — Lesinurad is metabolized
by CYP2C9 ...
The FDA has approved lesinurad (Zurampic –
Ironwood), a uric acid transporter 1 (URAT1)
inhibitor, for adjunctive treatment of gout-associated
hyperuricemia in patients whose serum uric acid
levels fail to reach goal with xanthine oxidase
inhibitor monotherapy.
Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy
The Medical Letter on Drugs and Therapeutics • Nov 07, 2016 (Issue 1507)
%
of that in healthy subjects.
146
The Medical Letter ® Vol. 58 (1507) November 7, 2016
The effect of eteplirsen ...
Eteplirsen (Exondys 51 – Sarepta), an antisense
oligonucleotide, has received accelerated approval
from the FDA for treatment of Duchenne muscular
dystrophy (DMD) in patients who have a mutation
of the dystrophin gene that is amenable to exon
51 skipping. It is the first drug to be approved for
treatment of DMD.
Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD
The Medical Letter on Drugs and Therapeutics • Oct 10, 2016 (Issue 1505)
was maintained
during a 28-week extension (PINNACLE-3) of these
trials.7
131
The Medical Letter ® Vol. 58 ...
The FDA has approved a fixed-dose combination of
the long-acting anticholinergic glycopyrrolate and
the long-acting beta2-adrenergic agonist (LABA)
formoterol (Bevespi Aerosphere – AstraZeneca) for
long-term maintenance treatment of patients with
chronic obstructive pulmonary disease (COPD).
Glycopyrrolate/formoterol is the fourth long-acting
anticholinergic/LABA combination to be approved in
the US, but the first to become available in a metered-dose
inhaler. Glycopyrrolate/indacaterol (Utibron
Neohaler), umeclidinium/vilanterol (Anoro Ellipta),
and tiotropium/olodaterol (Stiolto...
Sebelipase Alfa (Kanuma) for Lysosomal Acid Lipase Deficiency (online only)
The Medical Letter on Drugs and Therapeutics • Sep 26, 2016 (Issue 1504)
statistically significant. Lipid
levels improved and reductions in hepatic fat content
Letter ® Vol. 58 (1504 ...
The FDA has approved sebelipase alfa (Kanuma –
Alexion), a recombinant form of lysosomal acid lipase
(LAL), for enzyme replacement therapy in patients with
LAL deficiency. Sebelipase alfa is the first drug to be
approved in the US for treatment of LAL deficiency, a
rare autosomal recessive storage disease.